Quantum-Si (QSI) investor relations material

Strategic direction and technology development

• Focused on commercializing next-generation protein sequencing, with Platinum as the first-generation device and Proteus as the upcoming second-generation platform.

• Proteus architecture was announced in November last year, aiming for prototype sequencing by year-end and commercial launch in the second half of next year.

• Emphasis on maintaining milestone discipline, with regular updates and a major investor day planned for November to detail progress and future plans.

• Key technological advances include improved surface chemistry and compatibility of consumables and software between Platinum and Proteus.

• Ongoing development to achieve full coverage of all 20 amino acids, with significant improvements in sequencing output and a clear roadmap to completion.

Market evolution and commercialization

• Initial market focus was on academic centers, but expanded to biopharma and government/defense sectors due to shifting demand and funding dynamics.

• Established a global distribution network with 23 partners outside the U.S. and a U.S.-based distributor, building brand recognition and market presence.

• Developed operational capacity and supply chain investments post-launch, positioning for efficient Proteus rollout.

• Customer evangelism through publications and conference presentations has been key for both commercial traction and product development feedback.

• Application development team created to address unique customer needs and identify scalable new business opportunities, especially in post-translational modifications.

Product and software innovation

• Continuous evolution of library preparation and sequencing kits, with most chemistry and hardware compatible across generations.

• Leveraged AI and proprietary data, in partnership with NVIDIA, to accelerate development of new protein recognizers and improve sequencing performance.

• Regular software updates and cloud-based tools enable customers to access new analysis workflows and capabilities as they are developed.

• Customer-driven innovation has led to new kits and workflow optimizations, such as barcoding for biopharma and enzyme enhancements for specific research needs.

• Considering opening data access to third parties for tool development, mirroring trends in the DNA sequencing industry.